DENVER and BEVERLY, Mass., Oct. 22 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulltin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOFLES LTDA) will present the results of the first 95 fertility treatment cycles undertaken at the Center utilizing INVO Bioscience's INVOcell technology at the 66th Annual Meeting of the American Society for Reproductive Medicine on October 26, 2010 in Denver, Colorado.
The Annual Meeting of the American Society for Reproductive Medicine (ASRM) is one of the premier educational and professional networking conferences in the reproductive field. The theme for this year's event is "Taking Reproductive Medicine to New Heights." The event will feature a wide variety of postgraduate courses, lectures, symposia, roundtables, debates, abstracts, posters and videos focusing attention on the latest scientific developments in the field of reproductive medicine and their translation to clinical medicine.
Dr. Claude Ranoux, president of INVO Bioscience, commented, "We look forward with great anticipation to the CECOFLES presentation regarding the use of INVOcell in its initial treatment cycles. We are confident that INVOcell has performed well in these initial applications. Additionally, we are pleased that the study results have been accepted and will be unveiled at a prestigious conference the caliber of the ASRM."
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
Private Securities Litigation Reform Act of 1995
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Kathleen Karloff
INVO Bioscience, Inc.
978-878-9505 ext 504
SOURCE INVO Bioscience, Inc.